PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSecukinumab
Cosentyx(secukinumab)
Cosentyx (secukinumab) is an antibody pharmaceutical. Secukinumab was first approved as Cosentyx on 2015-01-14. It is used to treat ankylosing spondylitis and psoriatic arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, psoriasis, and psoriatic arthritis. The pharmaceutical is active against interleukin-17A.
Download report
Favorite
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Cosentyx (discontinued: Cosentyx)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Secukinumab
Tradename
Proper name
Company
Number
Date
Products
CosentyxsecukinumabNovartisN-125504 RX2015-01-21
4 products
CosentyxsecukinumabNovartisN-761349 RX2023-10-06
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cosentyxBiologic Licensing Application2026-08-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
psoriatic arthritisEFO_0003778D015535L40.5
ankylosing spondylitisEFO_0003898D013167M45
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AC: Interleukin inhibitors
— L04AC10: Secukinumab
HCPCS
No data
Clinical
Clinical Trials
267 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L404931111872
ArthritisD001168EFO_0005856M05-M1417152428
Psoriatic arthritisD015535EFO_0003778L40.5—3142726
SpondylarthritisD025241———2154122
SpondylitisD013166—M46.9—2144121
Ankylosing spondylitisD013167EFO_0003898M45—294318
Hidradenitis suppurativaD017497—L73.2——311115
Axial spondyloarthritisD000089183————5128
Rheumatoid arthritisD001172EFO_0000685M06.91431—8
Non-radiographic axial spondyloarthritisD000089202—M45.A——2125
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
UveitisD014605EFO_1001231H20.9—16——7
Juvenile arthritisD001171EFO_1002007M081—2—36
Polymyalgia rheumaticaD011111EFO_0008518M35.3123——6
Giant cell arteritisD013700EFO_1001209M31.6122——5
DermatitisD003872—L30.9—22——4
TendinopathyD052256EFO_1001434M77.9—13——4
Lupus nephritisD008181EFO_0005761———2——2
NephritisD009393—N05——2——2
ArteritisD001167EFO_0009011I77.6—11——2
HidradenitisD016575————2——2
Show 15 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35—3———3
SclerosisD012598———3———3
Crohn diseaseD003424EFO_0000384K50—2——13
Pyoderma gangrenosumD017511EFO_0006835L8812———2
PyodermaD011711—L08.012———2
Atopic dermatitisD003876EFO_0000274L20—2———2
Relapsing-remitting multiple sclerosisD020529EFO_0003929——2———2
Inflammatory bowel diseasesD015212EFO_0003767——1——12
Intestinal diseasesD007410—K63.9—1——12
Lichen planusD008010—L43—1———1
Show 13 more
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ColitisD003092EFO_0003872K52.9————11
TuberculosisD014376EFO_0000774A15-A19————11
Rheumatic diseasesD012216—M79.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSecukinumab
INNsecukinumab
Description
Secukinumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1743068
ChEBI ID—
PubChem CID—
DrugBankDB09029
UNII IDDLG4EML025 (ChemIDplus, GSRS)
Target
Agency Approved
IL17A
IL17A
Organism
Homo sapiens
Gene name
IL17A
Gene synonyms
CTLA8, IL17
NCBI Gene ID
3605
Protein name
interleukin-17A
Protein synonyms
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated protein 8, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin-17
Uniprot ID
Q5T2P0
Mouse ortholog
Il17a (16171)
interleukin-17A (Q62386)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cosentyx – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
164,284 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use